Analysis of Dermal Fibroblasts and Immune Cells During Systemic Sclerosis

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT05273138

Acronym

Skin-SSC

Enrollment

Registered

2022-03-10

Start date

2022-06-08

Completion date

2026-06-30

Last updated

2025-12-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Systemic Sclerosis

Keywords

Systemic sclerosis, Fibrosis, fibroblasts., Fibroblasts., Immune system., B lymphocytes.

Brief summary

The pathophysiology of systemic sclerosis (SSc) is still poorly understood and there are no effective treatments for this disease. SSc is a heterogeneous disease with varying severity. The heterogeneity of fibroblast profiles, observed in other fibrosing pathologies, has never been thoroughly explored in the skin of SSc patients. The immune system, and in particular B lymphocytes, plays a central role in the pathophysiology of SSc. The interactions between B lymphocytes and the cells responsible for excess collagen production, i.e. fibroblasts, are not fully elucidated The main objective is to analyze the heterogeneity of fibroblasts and infiltrating immune cells as well as their molecular signature in the skin of patients with SSc

Interventions

OTHERBlood sampling and skin biopsy

Blood sampling and skin biopsy

Study design

Observational model

CASE_CONTROL

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Yes

Inclusion criteria

* Man or woman over 18 years of age * With a systemic sclerosis meeting the ACR-EULAR 2013 criteria Having signed an informed consent * Being insured

Exclusion criteria

* Syndrome of overlap with another connective tissue disease according to the international diagnostic criteria * Immunosuppressive treatment within 12 months * Dosage of current corticosteroid therapy ≥10mg/d * Protected minors or adults * Pregnant or breastfeeding women * Deprived of their liberty * Persons in emergency situations * Persons who have refused or are unable to give informed consent

Design outcomes

Primary

Measure	Time frame
Single cell RNAseq transcriptomic analysis of skin	At inclusion

Secondary

Measure	Time frame
Single cell RNAseq transcriptomic analysis of the whole blood	At inclusion

Countries

France

Contacts

Primary ContactDavid Launay, MD,PhD

david.launay@chru-lille.fr0320445962

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026